Anti-CD20 Discontinuation Versus Continuation in People Aged Over 50 With Non-Active Multiple Sclerosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Moukhine Alexia, Rollot Fabien, Casey Romain, Collongues Nicolas, Vukusic Sandra, Mathey Guillaume, Dubessy Anne Laure, Ciron Jonathan, De Seze Jérôme, Ruet Aurélie, Labauge Pierre, Kwiatkowski Arnaud, Zephir Hélène, Papeix Caroline, Defer Gilles, Lebrun-Frenay Christine, Laplaud David Axel, Berger Eric, Thouvenot Eric, Pelletier Jean, Al Khedr Abdullatif, Casez Olivier, Bourre Bertrand, Wahab Abir, Magy Laurent, Camdessanché Jean-Philippe, Doghri Ines, Moulin Solène, Rivière Mariana Sarov, Hankiewicz Karolina, Santos Amélie Dos, Pottier Corinne, Manchon Eric, Aboab Jennifer, Tchikviladze Maia, David Thomas, Edan Gilles, Le Page Emmanuelle, Michel Laure, Kerbrat Anne, OFSEP Investigators
Аннотация
METHODS: This observational, multicenter, retrospective cohort study included 2283 patients from the French MS registry aged > 50, who had received at least two cycles of anti-CD20 and had experienced no relapses or MRI activity for at least one year prior to inclusion. Patients were classified as discontinuing or continuing therapy and 1:1 matched using a time-dependent propensity score. Outcomes were time to first relapse, inflammatory activity (relapse and/or MRI activity), confirmed disability accrual, and serious infection.
RESULTS: Among 1900 patients continuing therapy and 383 discontinuing, 224 in each group were matched (mean age = 57.7 ± 5.9 years; mean EDSS = 5.4 ± 1.7; median follow-up after matching = 34.8 [21.6-50.4] months). There were no significant differences between groups in time to first relapse (HR = 0.6, 95% CI 0.3-1.3, p = 0.2), inflammatory activity (HR = 0.9, 95% CI 0.5-1.4, p = 0.6), confirmed disability accrual (HR = 1.2, 95% CI 0.9-1.7, p = 0.2), and serious infections (HR = 1.0, 95% CI 0.6-1.8, p = 0.9).
INTERPRETATION: This retrospective study found no evidence of differences between stopping and continuing anti-CD20 therapy regarding relapse, inflammatory activity, disability accrual, or serious infections in older patients with long-standing non-active MS over a median 2.9-year follow-up.